



DAVID Y. IGE
GOVERNOR

DOUGLAS S. CHIN
LIEUTENANT GOVERNOR

**STATE OF HAWAII
OFFICE OF THE DIRECTOR
DEPARTMENT OF COMMERCE AND CONSUMER AFFAIRS**

335 MERCHANT STREET, ROOM 310
P.O. BOX 541
HONOLULU, HAWAII 96809
Phone Number: 586-2850
Fax Number: 586-2856
cca.hawaii.gov

CATHERINE P. AWAKUNI COLÓN
DIRECTOR

JO ANN M. UCHIDA TAKEUCHI
DEPUTY DIRECTOR

TO THE SENATE COMMITTEE ON
WAYS AND MEANS

TWENTY-NINTH LEGISLATURE
Regular Session of 2018

Friday, February 23, 2018
11:00 a.m.

WRITTEN TESTIMONY ONLY

TESTIMONY ON SENATE BILL NO. 2199, RELATING TO INSURANCE.

TO THE HONORABLE DONOVAN M. DELA CRUZ, CHAIR, AND MEMBERS OF THE
COMMITTEE:

The Department of Commerce and Consumer Affairs (“Department”) appreciates the opportunity to testify in strong support of S.B. 2199, Relating to Insurance. My name is Gordon Ito, and I am the Insurance Commissioner for the Department’s Insurance Division. This bill is a companion to H.B. 2146.

Section 1332 of the Patient Protection and Affordable Care Act (“ACA”) allows states to apply for a state innovation waiver to implement innovative ways to provide access to quality health care that is at least as comprehensive and affordable as would be provided absent the waiver, and to provide coverage to a comparable number of residents of the state as would be provided coverage absent a waiver.

Reinsurance programs in conjunction with section 1332 innovation waivers have been established in other states as a method to help mitigate premium increases in their individual health insurance markets. The waivers provide for “pass-through” funding from the federal government based on savings their reinsurance programs create. The

authority provided by this measure is necessary to allow the State to pursue a similar opportunity.

Thank you for the opportunity to testify in strong support of this measure.

Testimony of
Jonathan Ching
Government Relations Specialist

Before:
Senate Committee on Ways and Means
The Honorable Donovan M. Dela Cruz, Chair
The Honorable Gilbert S.C. Keith-Agaran, Vice Chair

February 23, 2018
11:00 a.m.
Conference Room 211

Re: SB2199, Relating to Insurance

Chair Dela Cruz, Vice-Chair Keith-Agaran, and committee members, thank you for this opportunity to provide testimony on SB2199, which authorizes the State to submit a section 1332 state innovation waiver proposal to the federal government and to implement the conditions of the waiver upon approval by the federal government.

Kaiser Permanente Hawaii SUPPORTS SB2199

As the committee is aware, significant uncertainties exist in the individual health insurance market. Last year, the federal government eliminated funding of Cost Sharing Reduction payments, which drove up premiums for many consumers seeking coverage in Hawai'i and across the nation. Both the elimination of the Cost Sharing Reduction payments and the elimination of the penalty associated with the individual mandate has resulted in further uncertainty about the future of the individual market. For this reason, we support the state's efforts to stabilize the individual market, including the creation of a statewide reinsurance program.

Although there is no solution as effective as an enforced individual mandate, an appropriately structured and funded reinsurance program is a step towards reducing individual premiums and promoting stability in the individual market. We saw the role the federal reinsurance program in partnership with risk adjustment played in supporting plans that enrolled higher-risk individuals, thereby protecting issuers against adverse selection within a market and encouraging them to offer products that serve all types of consumers. A state reinsurance program, if appropriately funded and structured, could support adequate levels of coverage while discouraging low-value plans. If appropriately structured, it could also benefit consumers by encouraging more health plan participation in markets where there isn't currently enough competition.

If appropriately and sustainably funded and structured, Kaiser Permanente Hawaii could support the implementation of a permanent, state-based reinsurance program in Hawai'i through a State

Innovation Waiver under Section 1332 of the Affordable Care Act (ACA). Similar to the transitional reinsurance program under ACA, we believe a state-based program should be claims-based since health plans have experience with the existing ACA framework. If implemented, the program should include a cap where federal risk adjustment starts (i.e. \$1 million in 2019), with a sufficiently high attachment point to encourage efficient claims management. We note that the Insurance Commissioner is in the process of retaining a third-party consultant to weigh various program design options.

In conclusion, to truly protect and preserve the individual market in Hawai'i, Kaiser Permanente Hawaii recommends that policymakers adopt a state-based individual mandate.

We look forward to having the opportunity to work with the Committee to further SB2199. Thank you for the opportunity to testify on this measure.



An Independent Licensee of the Blue Cross and Blue Shield Association

February 23, 2018

The Honorable Donovan M. Dela Cruz, Chair
The Honorable Gilbert S.C. Keith-Agaran, Vice Chair
Senate Committee on Ways and Means

Re: SB 2199 – Relating to Insurance

Dear Chair Dela Cruz, Vice Chair Keith-Agaran, and Members of the Committee:

The Hawaii Medical Service Association (HMSA) appreciates the opportunity to testify on SB 2199, that would allow the State to apply for and implement a waiver from certain provisions of the Patient Protection and Affordable Care Act of 2010 (ACA). HMSA supports SB 2199.

We understand this legislation to be a useful tool to allow the state to provide additional funding and innovative methods of pooling risk to cover health care for high-risk patients with costly medical claims. We look forward to the discussion on the details of the program including the funding mechanism.

Thank you for allowing us to testify on this measure.

Sincerely,

Pono Chong
Vice President, Government Relations

SB-2199

Submitted on: 2/21/2018 3:20:13 AM

Testimony for WAM on 2/23/2018 11:00:00 AM

Submitted By	Organization	Testifier Position	Present at Hearing
Younghi Overly	Individual	Comments	No

Comments:

Dear Chair Dela-Cruz, Vice-Chair Keith-Agaran, and Members of the Senate Committee on Ways and Means,

Thank you for this opportunity to submit a testimony with comments for S.B. 2199.

I have an inherited cancer syndrome and without healthcare insurance, I won't be able to afford the necessary medical tests to detect and treat various cancers in their early stage which I have been able to do so far. So while I understand the need to control high insurance premium costs for the broader pool of insured persons, I am concerned about what the premium costs for high cost insured persons like myself would be with the state reinsurance program. For my husband and I who work as independent consultants, the healthcare cost is already too high and I am afraid that the healthcare would no longer be affordable for me.

For first time in our lives, we wish we lived in another country, one with affordable healthcare. **Please commission a study which will look at both what it will cost to provide universal healthcare in Hawaii but also how we can reduce the total healthcare cost.** The "[Economic Analysis of Healthy California](#)" done by UMass shows that while universal coverage in California could increase the total cost by 10%, a single payer system with reduced administrative cost could decrease the total cost by 18%. Please figure out how to have affordable healthcare in Hawaii for my and other residents of Hawaii but also become a role model for other states.

Thank you for taking time to read my comment and I hope you would take my situation into consideration.

SB-2199

Submitted on: 2/21/2018 4:02:25 PM

Testimony for WAM on 2/23/2018 11:00:00 AM

Submitted By	Organization	Testifier Position	Present at Hearing
Javier Mendez-Alvarez	Individual	Oppose	No

Comments: